In non‐small cell lung cancer (NSCLC), several genetic mutations influencing therapy choices have been identified, including mutations in EGFR, ALK, ROS1, and BRAF [4, 5, 6, 7, 8, 9, 10, 11]. Here, EGFR is linked to non-small cell lung carcinoma.